Know Cancer

forgot password

An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.

Phase 2
18 Years
Not Enrolling
Relapsed Breast Cancer, Neoplasms, Breast

Thank you

Trial Information

An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.

Inclusion Criteria:

- Signed informed consent.

- Histologically/cytologically confirmed breast cancer;

If the disease is restricted to a solitary lesion, the neoplastic nature of the lesion
must be confirmed by cytology or histology.

- Measurable lesion(s) according to RECIST (Response Evaluation Criteria in Solid
Tumors) [Therasse, 2000].

- Documented amplification of the ErbB2 gene by fluorescence in situ hybridization
(FISH) or documented overexpression of the ErbB2 protein by 3+ IHC in primary or
metastatic tumor tissue.

- Subjects must have relapsed breast cancer where the disease progressed during or ≤ 12
months after completion of trastuzumab-containing therapy in the neoadjuvant or
adjuvant setting.

Note: Progression is defined using RECIST criteria, that is, either the appearance of new
lesions or a >=20% increase in the sum of longest diameter (LD).

- Subjects must not have received prior anti-cancer therapy for metastatic breast
cancer (MBC). Subjects who received prior antihormonal agents combined with
trastuzumab for the treatment of disease which first presented as ER positive MBC and
recurred while receiving trastuzumab or ≤ 3 months after completing this therapy are

- Subjects with stable central nervous system (CNS) metastases as confirmed by
computerized tomography (CT)/magnetic resonance imaging (MRI) are allowed. Treatment
with prophylactic anticonvulsants is permitted, unless listed within the Prohibited

- Subjects must have a baseline cardiac ejection fraction (LVEF) ³50% measured by
echocardiogram (ECHO) (or multigated acquisition (MUGA) scan if an ECHO cannot be
performed). The same modality used at baseline must be used for repeat assessment
throughout study. Only subjects with controlled or asymptomatic angina or
arrhythmias are eligible.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 2.

- Subjects must have archived tumor tissue from the initial diagnosis available for
analysis. If tissue from the initial diagnosis is not available, then tissue must be
obtained from a recurrent or metastatic site prior to initiating study treatment.

- Female ≥18 years.

- Subject must have adequate organ function as defined in Table 1.

- Table 1: Baseline Laboratory Values for Adequate Organ Function.



Absolute neutrophil count: ≥1.5 X 10^9/L

Hemoglobin: ≥9 g/dL

Platelets: ≥ 75 X 10^9/L


AST, ALT and Alkaline phosphatase: ≤ 2.5 X ULN

Unless concomitant docetaxel, then ≤ 1.5 x ULN for AST and ALT, with AP ≤ 2.5 x ULN

Unless documented liver metastasis, then ≤ 5 x ULN

Serum bilirubin: ≤ 2.0 X ULN

Albumin: ≥ 2.5 g/dL


Serum Creatinine: ≤ 1.5 mg/dL

- OR - Calculate Creatinine Clearance: ≥ 40 mL/min

1. Calculated by the Cockcroft and Gault Method [Cockcroft , 1976].

Exclusion Criteria:

- Pregnant or lactating females.

- Women of childbearing potential who do not practice approved contraceptive methods
(for example, intrauterine device [IUD], birth control pills, or barrier device)
beginning 2 weeks before the first dose of investigational product and for 28 days
after the final dose of investigational product.

- History of other malignancy. However, subjects who have been disease-free for 5
years, or subjects with a history of completely resected non-melanoma skin cancer or
successfully treated in situ carcinoma are eligible.

- Concurrent therapy given to treat cancer (chemotherapy, radiation therapy,
immunotherapy, biologic therapy, anti-hormonal therapy) while taking study

- Unresolved or unstable, serious toxicity from prior administration of another
investigational drug and/or of prior cancer treatment.

- Malabsorption syndrome or resection of the stomach or small bowel significantly
affecting gastrointestinal function.

- Have current active haptic or biliary disease (with excpetion of patients with
Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver
disease per investigator assessment).

- Concurrent disease or condition that, in the opinion of the physician, would make the
subject inappropriate for study participation or any serious medical disorder that
would interfere with the subject's safety (for example, uncontrolled infection, or
any psychiatric condition prohibiting understanding or rendering of informed

- Concurrent treatment with an investigational agent or participation in another
clinical trial involving investigational agents for anti-cancer therapy.

- Bisphosphonates may not be initiated after the first dose of study medication.

- Considered by the Investigator to have a life expectancy less than 3 months.

- Not able to swallow or retain oral medication.

- The subject with a known unmanageable hypersensitivity reaction or idiosyncrasy to
drugs chemically related to lapatinib or excipients and those related to
capecitabine, docetaxel, nab paclitaxel or their excipients.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Tumor Response

Outcome Description:

Overall tumor response is defined as the percentage of participants with a confirmed complete or partial tumor response per Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as the disappearance of all target lesions. CR could only be declared if all target and non-target lesions had disappeared. Partial response (PR) is defined as a decrease of 30% or greater in the sum of the longest diameter of target lesions.

Outcome Time Frame:

from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 wks; dependent on when participant discontinued study therapy due to disease progression, death, adverse event, of other reason)

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

November 2007

Completion Date:

March 2010

Related Keywords:

  • Relapsed Breast Cancer
  • Neoplasms, Breast
  • ErbB1
  • ErbB2
  • GW572016
  • lapatinib
  • Relapsed breast cancer
  • dual tyrosine kinase inhibitor
  • MBC
  • EGFR
  • Her-2/neu
  • FISH amplification
  • Breast Neoplasms
  • Neoplasms



GSK Investigational SiteLittle Rock, Arkansas  72205
GSK Investigational SiteBakersfield, California  93309
GSK Investigational SiteGainesville, Florida  32610
GSK Investigational SiteIndianapolis, Indiana  46260
GSK Investigational SiteNew Orleans, Louisiana  70112
GSK Investigational SiteDuluth, Minnesota  55805
GSK Investigational SiteAlbuquerque, New Mexico  87109
GSK Investigational SiteFort Worth, Texas  76104
GSK Investigational SiteSavannah, Georgia  31405
GSK Investigational SitePark Ridge, Illinois  60068
GSK Investigational SiteBaltimore, Maryland  21201
GSK Investigational SiteColumbia, South Carolina  29210
GSK Investigational SiteSalem, Virginia  24153
GSK Investigational SiteNew York, New York  10021
GSK Investigational SiteWashington, District of Columbia  20307-5001
GSK Investigational SiteHattiesburg, Mississippi  39401
GSK Investigational SiteEdison, New Jersey  08837
GSK Investigational SiteSalt Lake City, Utah  84107